Company Filing History:
1 out of 338 
1 out of 1,327 
Years Active: 2015
Title: Martin Kluger: Innovator in Tumor Necrosis Factor Receptor Modulation
Introduction
Martin Kluger is an accomplished inventor based in the United States. He has made significant contributions to the field of medical research, particularly in the modulation of tumor necrosis factor receptors. His work focuses on therapeutic methods that can potentially treat various disease conditions.
Latest Patents
Martin Kluger holds a notable patent titled "Selective Modulation Of Tumour Necrosis Factor Receptors In Therapy." This invention relates to the identification and characterization of specific cellular responses associated with tumor necrosis factor receptor 1 (TNFR1) and tumor necrosis factor receptor 2 (TNFR2). The selective modulation of these responses may be beneficial in promoting or inhibiting cell growth, which is crucial in treating diseases such as cardiovascular and kidney diseases. The patent also provides therapeutic methods employing selective TNFR1 and TNFR2 modulators, along with screening methods for identifying these modulators.
Career Highlights
Throughout his career, Martin Kluger has worked with prestigious institutions, including Yale University and Cambridge Enterprise Limited. His experience in these organizations has allowed him to advance his research and contribute to the scientific community.
Collaborations
Martin has collaborated with notable individuals in his field, including John Bradley and Jordan S. Pober. These collaborations have further enriched his research and innovation efforts.
Conclusion
Martin Kluger is a prominent figure in the field of tumor necrosis factor receptor modulation. His innovative work has the potential to impact therapeutic approaches for various diseases.